article

Expert view: High-throughput analytics for smarter cell-line development

Posted: 1 June 2020 | | No comments yet

Combine titer and glycan screening during clone selection and cell culture optimisation to make more informed choices sooner, significantly reducing the development time for therapeutic antibodies.

Glycosylation is a critical antibody quality attribute linked directly to the efficacy and safety of commercial biologics. While there are various methodologies available for glycan analysis, there is also an increasing need for the development of high-throughput approaches applicable to early stage cell-line development. Octet instruments offer cell-line development scientists a platform for the rapid titer of antibody clones and sialic acid content screening. Combining the sialic acid content data with titer provides in-depth knowledge that can facilitate more informed decisions.











To read this expert view in full, please complete the form below. By clicking submit you confirm that you accept our terms and conditions and privacy policy.


*

*

*

*

*

*

*

*

This content is provided to you for free thanks to the kind support of our sponsor: FortéBio

Related organisations

Send this to a friend